PDF herunterladen
Horm Metab Res 2003; 35(11/12): 794-801
DOI: 10.1055/s-2004-814152
Original
© Georg Thieme Verlag Stuttgart · New York

Expression of the Insulin-like Growth Factor-I Receptor in Primary Breast Cancer and Lymph Node Metastases: Correlations with Estrogen Receptors α and β

M.  Koda1 , S.  Sulkowski1 , C.  Garofalo2 , L.  Kanczuga-Koda1 , M.  Sulkowska1 , E.  Surmacz2
  • 1Department of Clinical Pathology, Medical University of Bialystok, Poland
  • 2Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, USA.
Weitere Informationen

Publikationsverlauf

Received 9 September 2003

Accepted after Revision 13 October 2003

Publikationsdatum:
07. Januar 2004 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Erratum zu diesem Artikel:

Expression of the Insulin-like Growth Factor-I Receptor in Primary Breast Cancer and Lymph Node Metastases: Correlations with Estrogen Receptors α and β Horm Metab Res 2004; 36(01): 73
DOI: 10.1055/s-2004-814356

Abstract

Numerous laboratory studies and some epidemiological data have suggested the involvement of the insulin-like growth factor-I receptor (IGF-IR) in breast cancer development and progression. However, data on IGF-IR expression in human tissues, including breast cancer sections, are limited and often inconsistent. We therefore examined by immunohistochemistry the expression of IGF-IR in primary tumors and breast cancer metastases to lymph nodes, and correlated IGF-IR positivity with estrogen receptor (ER) status and selected clinicopathological features. We found that 1) IGF-IR was expressed in primary tumors as well as in lymph node metastases, but the expression in primary tumors was more frequent (56 % vs. 44.4 %); 2) IGF-IR expression in primary tumors was associated with negative node status (p < 0.033); 3) in node-negative primary tumors, IGF-IR positively correlated with ERβ (p < 0.008; r = 0.538), but not with ERα, tumor size or grade; 4) both IGF-IR-positive and IGF-IR-negative primary tumors were found to produce IGF-IR-positive as well as IGF-IR-negative metastases; 5) in metastases, IGF-IR expression did not associate with ERα, ERβ or any of the studied pathobiological markers. The results suggest that IGF-IR could become a viable pharmaceutical target in breast cancer therapy, but such therapy should be based on IGF-IR assessment in primary tumor and metastasis in each potential patient.

Key words

Breast Cancer - Lymph Node Metastasis - Insulin-like Growth Factor-I receptor - Estrogen Receptor α - Estrogen Receptor β

References

  • 1 Sasco A J, Kaaks R, Little R E. Breast cancer: occurrence, risk factors and hormone metabolism.  Expert Rev Anticancer Ther. 2003;  3 546-562
    CrossrefPubMedGoogle Scholar
  • 2 Surmacz E. Function of the IGF-I receptor in breast cancer.  J Mammary Gland Biol Neoplasia. 2000;  5 95-105
    CrossrefPubMedGoogle Scholar
  • 3 Sachdev D, Yee D. The IGF system and breast cancer.  Endocr Relat Cancer. 2001;  8 197-209
    CrossrefPubMedGoogle Scholar
  • 4 Yee D. Lee AV. Crosstalk between the insulin-like growth factors and estrogens in breast cancer.  J Mamm Gland Biol Neopl. 2000;  5 07-115
    PubMedGoogle Scholar
  • 5 Pollak M. Insulin-like growth factor physiology and cancer risk.  Eur J Cancer. 2000;  36 1224-1228
    CrossrefPubMedGoogle Scholar
  • 6 Turner B C, Haffty B G, Narayanan L, Yuan J, Havre P A, Gumbs A A, Kaplan L, Burgaud J L, Carter D, Baserga R, Glazer P M. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation.  Cancer Res. 1997;  57 3079-3083
    PubMedGoogle Scholar
  • 7 Dunn S E, Hardman R A, Kari F W, Barrett J C. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs.  Cancer Res. 1997;  57 2687-2693
    PubMedGoogle Scholar
  • 8 Gooch J L, van den Berg C L, Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects.  Breast Cancer Res Treat. 1999;  56 1-10
    CrossrefPubMedGoogle Scholar
  • 9 Mauro L, Salerno M, Morelli C, Boterberg T, Bracke M E, Surmacz E. Role of the IGF-I receptor in the regulation of cell-cell adhesion: implications in cancer development and progression.  J Cell Physiol. 2003;  194 108-116
    CrossrefPubMedGoogle Scholar
  • 10 Bartucci M, Morelli C, Mauro L, Ando' S, Surmacz E. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.  Cancer Res. 2001;  61 6747-6754
    PubMedGoogle Scholar
  • 11 Guvakova M A, Surmacz E. The activated insulin-like growth factor I receptor induces depolarization in breast epithelial cells characterized by actin filament disassembly and tyrosine dephosphorylation of FAK, Cas, and paxillin.  Exp Cell Res. 1999;  251 244-255
    CrossrefPubMedGoogle Scholar
  • 12 Pennisi P A, Barr V, Nunez N P, Stannard B, Le Roith D. Reduced expression of insulin-like growth factor I receptors in MCF-7 breast cancer cells leads to a more metastatic phenotype.  Cancer Res. 2002;  62 6529-6537
    PubMedGoogle Scholar
  • 13 Guvakova M A, Surmacz E. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells.  Exp Cell Res. 1997;  231 149-162
    CrossrefPubMedGoogle Scholar
  • 14 Doerr M, Jones J. The roles of integrins and extracellular matrix proteins in the IGF-IR-stimulated chemotaxis of human breast cancer cells.  J Biol Chem. 1996;  271 2443-2447
    CrossrefPubMedGoogle Scholar
  • 15 Dunn S E, Ehrlich M, Sharp N JH, Reiss K, Solomon G, Hawkins R, Baserga R, Barrett J C. A dominant negative mutant of the insulin-like growth factor I receptor inhibits the adhesion, invasion and metastasis of breast cancer.  Cancer Res. 1998;  58 3353-3361
    PubMedGoogle Scholar
  • 16 Surmacz , E . Growth factor receptors as therapeutic targets: Strategies to inhibit the insulin-like growth factor I receptor.  Oncogene. 2003;  22 6589-6597
    CrossrefPubMedGoogle Scholar
  • 17 Dupont J, Karas M, LeRoith D. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components.  J Biol Chem. 2000;  275 35 893-35 901
    PubMedGoogle Scholar
  • 18 Fournier B, Gutzwiller S, Dittmar T, Matthias T G, Steenbergh T, Matthias P. Estrogen receptor (ER)αlpha, but not ER-beta, mediates regulation of the insulin-like growth factor I gene by antiestrogens. J. Biol.  Chem.. 2001;  276 35 444-35 449
    PubMedGoogle Scholar
  • 19 Jackson J G, White M F, Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells.  J Biol Chem. 1998;  273 9994-10 003
    CrossrefPubMedGoogle Scholar
  • 20 Lee A V, Jackson J G, Gooch J L, Hilsenbeck , SG , Coronado-Heinsohn E, Osborne C K, Yee D. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.  Mol Endocrin. 1999;  10 787-796
    PubMedGoogle Scholar
  • 21 Mauro L, Salerno M, Panno M L, Bellizzi D, Sisci D, Miglietta A, Surmacz E, Ando S. Estradiol increases IRS-1 gene expression and insulin signaling in breast cancer cells.  Biochem Biophys Res Commun. 2001;  288 85-689
    PubMedGoogle Scholar
  • 22 Molloy C A, May F EB, Westley B R. Insulin receptor substrate 1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line.  J Biol Chem. 2000;  275 12 565-12 571
    PubMedGoogle Scholar
  • 23 Morelli C, Garofalo C, Bartucci M, Surmacz E. Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells.  Oncogene. 2003;  22 4007-4016
    CrossrefPubMedGoogle Scholar
  • 24 Stewart A J, Johnson M D, May F E, Westley B R. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells.  J Biol Chem. 1990;  265 21 172-21 178
    PubMedGoogle Scholar
  • 25 Kleinman D, Karas M, Roberts C T Jr, LeRoith D, Phillip M, Segev Y, Levy J, Sharoni Y. Modulation of insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol.  Endocrinology. 1995;  136 2531-2537
    CrossrefPubMedGoogle Scholar
  • 26 Salerno M, Sisci D, Mauro L, Guvakova M A, Ando S, Surmacz E. Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells.  Int J Cancer. 1999;  81 299-304
    CrossrefPubMedGoogle Scholar
  • 27 Guvakova M A, Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells.  Cancer Res. 1997;  57 2606-2610
    PubMedGoogle Scholar
  • 28 Chan T W, Pollak M, Huynh H. Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780.  Clin Cancer Res. 2001;  7 2545-2554
    PubMedGoogle Scholar
  • 29 Huynh H, Nickerson T, Yang X, Pollak M. Regulation of insulin-like growth factor I receptor by the pure antiestrogen ICI 182,780.  Clin Cancer Res. 1996;  265 2037-2042
    PubMedGoogle Scholar
  • 30 Freiss G, Puech C, Vignon F. Extinction of insulin-like growth factor-I mitogenic signaling by antiestrogen-stimulated Fas-associated protein tyrosine phosphatase-1 in human breast cancer cells.  Mol Endocrinol. 1998;  12 568-579
    CrossrefPubMedGoogle Scholar
  • 31 Parisot J P, Hu X F, DeLuise M, Zalcberg J R. Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line.  Br J Cancer. 1999;  79 693-700
    CrossrefPubMedGoogle Scholar
  • 32 Peyrat J P, Bonneterre J. Type 1 IGF receptor in human breast diseases.  Breast Cancer Res Treat. 1992;  22 59-67
    CrossrefPubMedGoogle Scholar
  • 33 Pezzino V, Papa V, Milazzo G, Gliozzo B, Russo P, Scalia P L. Insulin-like growth factor-I (IGF-I) receptors in breast cancer.  Ann N Y Acad Sci. 1996;  784 189-201
    PubMedGoogle Scholar
  • 34 Happerfield L C, Miles D W, Barnes D M, Thomsen L L, Smith P, Hanby A. The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue.  J Pathol. 1997;  183 412-417
    PubMedGoogle Scholar
  • 35 Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J, Mayer D. Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer.  Int J Cancer. 2000;  89 506-513
    CrossrefPubMedGoogle Scholar
  • 36 Railo M J, von Smitten K, Pekonen F. The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients.  Eur J Cancer. 1994;  30 307-311
    CrossrefPubMedGoogle Scholar
  • 37 Foekens J A, Portengen H, Janssen M, Klijn J G. Insulin-like growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer.  Cancer. 1989;  63 2139-2147
    PubMedGoogle Scholar
  • 38 Jammes H, Peyrat J P, Ban E, Vilain M O, Haour F, Djiane J, Bonneterre J. Insulin-like growth factor 1 receptors in human breast tumour: localization and quantification by histo-autoradiographic analysis.  Br J Cancer. 1992;  66 248-253
    PubMedGoogle Scholar
  • 39 Resnik J L, Reichart D B, Huey K, Webster N JG, Seely B L. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer.  Cancer Res. 1998;  58 1159-1164
    PubMedGoogle Scholar
  • 40 Peyrat J P, Bonneterre J, Beuscart R, Djiane J, Demaille A. Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors.  Cancer Res. 1988;  48 6429-6433
    PubMedGoogle Scholar
  • 41 Bonneterre J, Peyrat J P, Beuscart R, Demaille A. Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer.  Cancer Res. 1990;  50 6931-6935
    PubMedGoogle Scholar
  • 42 Papa V, Gliozzo B, Clark G M, McGuire W L, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine I D, Pezzino V. Insulin-like growth factor I receptors are overexpressed and predict a low risk in human breast cancer.  Cancer Res. 1993;  53 3736-3740
    PubMedGoogle Scholar
  • 43 Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, Siddle K, Goldfine I D, Belfiore A. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling.  Clin Cancer Res. 1999;  5 1935-1944
    PubMedGoogle Scholar
  • 44 Pekonen F, Partanen S, Makinen T, Rutanen E M. Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer.  Cancer Res. 1988;  48 1343-1347
    PubMedGoogle Scholar
  • 45 Lee A V, Hilsenbeck S G, Yee D. IGF-I system components as prognostic markers in breast cancer.  Breast Cancer Res Treat. 1998;  47 295-302
    CrossrefPubMedGoogle Scholar
  • 46 Sepp-Lorenzino L, Rosen N, Lebwohl D. Insulin and insulin-like growth factor signaling are defective in MDA-MB-468 human breast cancer cell line.  Cell Growth Differen. 1994;  5 1077-1083
    PubMedGoogle Scholar
  • 47 Peyrat J P, Bonneterre J, Dusanter-Fourt I, Leroy-Martin B, Djiane J, Demaille A. Characterization of insulin-like growth factor 1 receptors (IGF1-R) in human breast cancer cell lines.  Bull Cancer. 1989;  76 311-319
    PubMedGoogle Scholar
  • 48 Jackson J G, Yee D. IRS-1 expression and activation are not sufficient to activate downstream pathways and enable IGF-I growth response in estrogen receptor negative breast cancer cells.  Growth Horm IGF Res. 1999;  9 280-289
    PubMedGoogle Scholar
  • 49 Arteaga C L, Kitten L J, Coronado E B, Jacobs S, Kull F C Jr, Allred D C, Osborne C K. Blockade of the type I somatomedin receptor inhibits growth of human breats cancer cells in athymic mice.  J Clin Invest. 1989;  84 1418-1423
    PubMedGoogle Scholar
  • 50 Dunn S E, Ehrlich M, Sharp N, Reiss K, Solomon G, Hawkins R, Baserga R, Barrett J. A dominant negative mutant of the insulin-like growth factor I receptor inhibits the adhesion, invasion and metastasis of breast cancer.  Cancer Res. 1998;  58 3353-3361
    PubMedGoogle Scholar
  • 51 Bloom H JG, Richardson W W. Histological grading and prognosis in breast cancer.  Br J Cancer. 1957;  11 359-377
    PubMedGoogle Scholar
  • 52 Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human.  Nucleic Acids Res. 1998;  26 3505-3512
    CrossrefPubMedGoogle Scholar
  • 53 Pettersson K, Delaunay F, Gustafsson J A. Estrogen receptor beta acts as a dominant regulator of estrogen signaling.  Oncogene. 2000;  19 4970-4978
    CrossrefPubMedGoogle Scholar
  • 54 Pettersson K, Grandien K, Kuiper G G, Gustafsson J A. Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha.  Mol Endocrinol. 1997;  11 1486-1496
    CrossrefPubMedGoogle Scholar
  • 55 Roger P, Sahla M E, Makela S, Gustafsson J A, Baldet P, Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.  Cancer Res. 2001;  61 2537-2541
    PubMedGoogle Scholar
  • 56 Hall J M, McDonnell D P. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens.  Endocrinology. 1999;  140 5566-5578
    CrossrefPubMedGoogle Scholar
  • 57 Jarvinen T A, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer.  Am J Pathol. 2000;  156 29-35
    PubMedGoogle Scholar
  • 58 Jensen E V, Cheng G, Palmieri C, Saji S, Makela S, van Noorden S, Wahlstorm T, Warner M, Coombes R C, Gustafsson J A. Estrogen receptors and proliferation markers in primary and recurrent breast cancer.  Proc Natl Acad Sci USA. 2001;  98 15 197-15 202
    PubMedGoogle Scholar
  • 59 Speirs V, Kerin M J. Prognostic significance of oestrogen receptor beta in breast cancer.  Br J Surg. 2000;  87 405-409
    CrossrefPubMedGoogle Scholar
  • 60 Speirs V, Malone C, Walton D S, Kerin M J, Atkin S L. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients.  Cancer Res. 1999;  59 5421-5424
    PubMedGoogle Scholar
  • 61 Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, Hayashi S. Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7.  Oncogene. 2003;  22 5011-5020
    CrossrefPubMedGoogle Scholar
  • 62 Saji S, Omoto Y, Shimizu C, Horiguchi S, Watanabe T, Funata N, Hayash S, Gustafsson J A, Toi M. Clinical impact of assay of estrogen receptor beta cx in breast cancer.  Breast Cancer. 2002;  9 303-307
    CrossrefPubMedGoogle Scholar
  • 63 Witte D, Chirala M, Younes A, Li Y, Younes M. Estrogen receptor beta is expressed in human colorectal adenocarcinoma.  Hum Pathol. 2001;  32 940-944
    CrossrefPubMedGoogle Scholar
  • 64 Vidal O, Kindblom L G, Ohlsson C. Expression and localization of estrogen receptor-beta in murine and human bone.  J Bone Miner Res. 1999;  14 923-929
    PubMedGoogle Scholar
  • 65 Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, Watanabe T, Hayashi S, Gustafsson J A, Toi M. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor.  Cancer Res. 2002;  62 4849-5483
    PubMedGoogle Scholar
  • 66 Iwao K, Miyoshi Y, Egawa C, Ikeda N, Noguchi S. Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers.  Int J Cancer. 2000;  88 733-736
    CrossrefPubMedGoogle Scholar
  • 67 Tong D, Schuster E, Seifert M, Czerwenka K, Leodolte S, Zeillinger R. Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines.  Breast Cancer Res Treat. 2002;  71 249-255
    CrossrefPubMedGoogle Scholar

E. Surmacz, Ph. D. 

Kimmel Cancer Center

Thomas Jefferson University · 233S 10 St. · BLSB 631 · Philadelphia, PA 19107 · USA

Telefon: + 1 (215) 5034512

Fax: + 1 (215) 9230249

eMail: eva.surmacz@jefferson.edu